MAXHEALTH1,033.10

Max Healthcare Institute Ltd.

· Pharma & Health
₹ CrorePeersAPOLLOHOSPFORTISMEDANTADRREDDYCIPLASUNPHARMADIVISLABTORNTPHARMMcap ₹1.01L Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation245.0359.4446.5
+ Finance Costs37.6148.8215.0
+ Interest Income-152.9-105.5-109.7
+ Fair Value (Gains) / Losses14.00.00.0
+ Share-based Payments49.654.648.3
+ Unrealised FX (Gain) / Loss0.90.72.7
+ Other Non-cash Items-9.440.30.0
+ Other Reconciling Items0.00.0-10.5
Changes in Working Capital
+ Inventories5.9-19.2-8.7
+ Trade Receivables — Current-115.0-209.1-323.1
+ Trade Receivables — Non-current6.30.00.0
+ Other Financial Assets — Current-8.110.9-13.1
+ Other Financial Assets — Non-current-14.10.00.0
+ Other Current Assets2.1-22.7-23.8
+ Other Non-current Assets-21.80.00.0
+ Trade Payables — Current78.381.573.3
+ Other Financial Liabilities — Non-current-118.40.00.0
+ Other Current Liabilities14.0-0.64.2
+ Provisions — Current3.535.228.6
+ Provisions — Non-current8.20.00.0
Cash from Operating Activities
Profit Before Tax (per I/S)1,365.31,406.41,675.61,711.5
+ Total Adjustments (incl. Working Capital)25.8374.2329.6
Cash from Operations (pre-tax)1,391.11,780.62,005.2
+ Income Taxes Paid269.3320.9371.9
Cash from Operating Activities1,121.81,459.71,633.3
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)778.8965.51,484.5
+ Disp of Fixed Assets6.30.016.1
+ Acq of Investment Property7.20.00.0
+ Disp of Investment Property0.06.40.0
+ Purchase of Investments (Equity / Debt)0.00.83.9
+ Sale of Investments (Equity / Debt)0.00.01.3
+ Acq of Subsidiaries / Businesses (net)631.2624.70.0
+ Loans & Advances Made0.0245.0420.0
+ Loans & Advances Repaid0.00.057.0
+ Interest Received — Investing153.295.1118.8
+ Other Inflows / (Outflows) — Investing-27.8102.826.3
Cash from Investing Activities-1,285.5-1,631.7-1,689.0
Cash from Financing Activities
+ Proceeds from Issue of Shares0.90.20.0
+ Proceeds from Exercise of Stock Options0.00.033.8
+ Proceeds from Borrowings642.01,349.5567.7
+ Repayment of Borrowings563.91,053.7143.8
+ Payment of Lease Liabilities58.4173.626.1
+ Interest Paid187.4140.6226.8
+ Dividends Paid97.0145.6145.6
Cash from Financing Activities-263.7-163.859.3
Net Changes in Cash (pre-FX)-427.4-335.93.6
+ Effect of FX Rate Changes on Cash-1.80.10.6
Net Changes in Cash-429.2-335.84.2
Closing Cash979.8661.2665.8
Reference Items
EBITDA1,492.11,848.82,242.82,318.4
EBITDA Margin %27.6026.3026.7926.61
Free Cash Flow (CFO − Capex)343.0494.1148.8148.8
Free Cash Flow to Equity2,064.8390.1
Free Cash Flow per Basic Share3.525.081.531.53
Price to Free Cash Flow675.68
Cash Flow to Net Income1.061.361.13
Cash Paid for Taxes269.3320.9371.9
Cash Paid for Interest187.4140.6226.8
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 146%.